CCCC vs SPGI · rev $35.6M vs P/E 27, rev $15.34B
C4 Therapeutics Inc (CCCC) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
CCCC currently screens at market cap $425.7M. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the CCCC and SPGI stock pages for the full models.
Not investment advice.